Compounds > sb 201993
Page last updated: 2024-12-11

sb 201993

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(E)-3-((((6-(2-carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)benzoic acid: structure given in first source; a competitive LTB(4) receptor antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6435820
CHEMBL ID422598
SCHEMBL ID1893839
SCHEMBL ID1893835
MeSH IDM0221999

Synonyms (18)

Synonym
sb-201993
CHEMBL422598 ,
3-{6-((e)-2-carboxy-vinyl)-5-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-ylmethylsulfanylmethyl}-benzoic acid
3-{6-(2-carboxy-vinyl)-5-[8-(4-methoxy-phenyl)-octyloxy]-pyridin-2-ylmethylsulfanylmethyl}-benzoic acid (sb201993)
3-{6-((e)-2-carboxy-vinyl)-5-[6-(4-methoxy-phenyl)-hexyloxy]-pyridin-2-ylmethylsulfanylmethyl}-benzoic acid
bdbm50037385
sb 201993
L009321
150399-22-7
benzoic acid, 3-((((6-(2-carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)-, (e)-
(e)-3-((((6-(2-carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)benzoic acid
4twc061lpm ,
unii-4twc061lpm
SCHEMBL1893839
SCHEMBL1893835
3-((((6-(2-carboxyethenyl)-5-((8-(4-methoxyphenyl)octyl)oxy)-2-pyridinyl)methyl)thio)methyl)benzoic acid (e)
sb201993
3-[[6-[(e)-2-carboxyethenyl]-5-[8-(4-methoxyphenyl)octoxy]pyridin-2-yl]methylsulfanylmethyl]benzoic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Leukotriene B4 receptor 1Homo sapiens (human)IC50 (µMol)0.13100.00080.30913.2500AID102468
Leukotriene B4 receptor 1Homo sapiens (human)Ki0.00710.00010.51267.0000AID102632; AID102635; AID102637; AID102658
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
muscle contractionLeukotriene B4 receptor 1Homo sapiens (human)
inflammatory responseLeukotriene B4 receptor 1Homo sapiens (human)
immune responseLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
neuropeptide signaling pathwayLeukotriene B4 receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
nucleotide bindingLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
leukotriene B4 receptor activityLeukotriene B4 receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
plasma membraneLeukotriene B4 receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID76800Compound was tested in vivo inhibitory activity against AA induced ear edema1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID102632Binding affinity against LTB4 receptors in human PMNs1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.
AID102635Binding affinity at leukotriene B4 receptor on intact human PMNs by displacement of [3H]LTB4.1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.
AID160517Concentration of test compound required to inhibit 50% LTB4-induced calcium mobilization in intact human PMNs1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.
AID102658Compound was tested for binding affinity against Leukotriene B4 receptor1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID225838Effect on Arachidonic Acid-Induced Mouse Ear Inflammation expressed as percent inhibition of MPO at 100 ug/ear of topical administration1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.
AID136468Compound was tested for its effect on mouse ear for reduction of PMN infiltration1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.
AID89243Compound was tested in vitro for inhibitory activity in LTB4 induced Ca mobilization1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID131369Effective concentration required per ear of mouse for inhibition of neutrophil infiltration1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.
AID131542Effective dose for neutrophil infiltration after administration of 1 mg of arachidonic acid in mouse ear1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.
AID160352Inhibitory concentration against LTB4 induced degranulation in human PMNs1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.
AID102637Inhibition of [3H]LTB4 binding to human neutrophils1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.
AID225501Dose required to inhibit 50% of arachidonic acid-induced inflammation after topical administration obtained from dose-response curves1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.
AID160518Concentration of test compound required to inhibit 50% LTB4-induced degranulation of human PMNs1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.
AID131178Compound was tested in vivo inhibitory activity against LTB4 induced mouse peritonitis (orally)1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
AID131367Effective concentration required for inhibition of LTB4-induced (250 ng/mL) PMN infiltration1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.
AID131540Effective dose for edematous response after administration of 1 mg of arachidonic acid in mouse ear1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.
AID130879Inhibition of LTB4-induced PMN infiltration at 250 ng/mL in mouse1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.
AID225841Effect on Arachidonic Acid-Induced Mouse Ear Inflammation expressed as percent inhibition of MPO at 50 mg/kg of oral administration1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.
AID131368Effective concentration required per ear of mouse for inhibition of edematous response1994Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.
AID102468Inhibitory concentration against LTB4 receptors in human PMNs1993Journal of medicinal chemistry, Sep-03, Volume: 36, Issue:18
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.
AID147689Compound was tested in vitro inhibitory activity against LBT4 induced neutrophil degranulation1996Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14
Modulators of leukotriene biosynthesis and receptor activation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's5 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ly 171883
LY 171883: structure in first source; leukotriene receptor antagonist. tomelukast : A member of the class of acetophenones that is 1-phenylethanone substituted at position 2 by a hydroxy group, a propyl group at position 3 and a 4-(1H-tetrazol-5-yl)butoxy group at position 4. A leukotriene antagonist, it exhibits anti-asthmatic activity.		3.0910acetophenones;
aromatic ether;
phenols;
tetrazoles		anti-asthmatic drug;
leukotriene antagonist
ono 1078
pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist		3.0910chromones
pf 5901
alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol: structure given in first source; platelet activating factor antagonist		3.0910quinolines
ici 204,219
zafirlukast: a leukotriene D4 receptor antagonist		3.0910carbamate ester;
indoles;
N-sulfonylcarboxamide		anti-asthmatic agent;
leukotriene antagonist
ablukast
[no description available]		3.0910
zileuton
[no description available]		3.09101-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
wy 48252
Wy 48252: leukotriene D4 antagonist		3.0910
pobilukast
pobilukast: a leukotriene receptor antagonist; an antiasthmatic agent; structure in first source; RN refers to (R-(R*,S*)-isomer		3.0910
fpl 55712
FPL 55712: inhibitor of SRS-A and LTC4 and LTD4 receptors		3.0910aromatic ketone
sc 41930
SC 41930: leukotriene B4 receptor antagonist; structure in first source		3.4920
l 648051
L 648051: antagonist of leukotriene D4 receptor; structure in first source		3.0910
ly 255283
LY 255283: structure given in UD; leukotriene B4 antagonist		3.0910aromatic ketone
bay x 1005
2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid: inhibits synthesis of leukotriene B4 and 5-hydroxyeicosatetraenoic acid; inhibits five-lipoxygenase activating protein(FLAP)and leukotriene A4 hydrolase(LTA4H); structure given in first source;		3.0910
sr 2640
SR 2640: leukotriene D4 and E4 antagonist		3.0910quinolines
rg 12525
RG 12525: leukotriene D4 antagonist; structure in first source		3.0910
ici d2138
ICI D2138: structure given in first source; inhibitor of leukotriene B4 synthesis		3.0910
rg 14893
RG 14893: structure in first source; leukotriene B4 receptor antagonist		2.3920
ly 293111
LY 293111: a leukotriene B4 receptor antagonist; structure given in first source		3.0910aromatic ether
7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-2h-1-benzopyran-2-propanoic acid
7-(3-(2-(cyclopropylmethyl)-3-methoxy-4-((methylamino)carbonyl)phenoxy)propoxy)-3,4-dihydro-8-propyl-2H-1-benzopyran-2-propanoic acid: structure in first source; inhibits leukotriene B4 receptors		3.0910
via 2291
atreleuton: structure given in first source		3.0910
l 663536
MK-886: orally active leukotriene biosynthesis inhibitor. 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid : A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase.		3.0910aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes		antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist
leukotriene b4
Leukotriene B4: The major metabolite in neutrophil polymorphonuclear leukocytes. It stimulates polymorphonuclear cell function (degranulation, formation of oxygen-centered free radicals, arachidonic acid release, and metabolism). (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene B4 : A leukotriene composed of (6Z,8E,10E,14Z)-icosatetraenoic acid having (5S)- and (12R)-hydroxy substituents. It is a lipid mediator of inflammation that is generated from arachidonic acid via the 5-lipoxygenase pathway.		2.6830dihydroxy monocarboxylic acid;
hydroxy polyunsaturated fatty acid;
leukotriene;
long-chain fatty acid		human metabolite;
mouse metabolite;
plant metabolite;
vasoconstrictor agent
montelukast
montelukast: a leukotriene D4 receptor antagonist		3.0910aliphatic sulfide;
monocarboxylic acid;
quinolines		anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist
12-hydroxy-5,8,10,14-eicosatetraenoic acid
12-Hydroxy-5,8,10,14-eicosatetraenoic Acid: A lipoxygenase metabolite of ARACHIDONIC ACID. It is a highly selective ligand used to label mu-opioid receptors in both membranes and tissue sections. The 12-S-HETE analog has been reported to augment tumor cell metastatic potential through activation of protein kinase C. (J Pharmacol Exp Ther 1995; 274(3):1545-51; J Natl Cancer Inst 1994; 86(15):1145-51)		210
bwa 4c
[no description available]		3.0910
ono 4057
ONO-LB 457: LTB4 receptor antagonist; structure given in first source		3.7730
ticolubant
Ticolubant: a leukotriene B4 antagonist		3.4920
bay x 7195
BAY x 7195: structure given in first source		3.0910
ly 223982
LY 223982: RN & structure in first source; leukotriene B4 antagonist		3.7730
cp 105696
CP 105696: a leukotriene B4 receptor antagonist; structure in first source		3.0910
calcimycin
Calcimycin: An ionophorous, polyether antibiotic from Streptomyces chartreusensis. It binds and transports CALCIUM and other divalent cations across membranes and uncouples oxidative phosphorylation while inhibiting ATPase of rat liver mitochondria. The substance is used mostly as a biochemical tool to study the role of divalent cations in various biological systems.		210benzoxazole
mk 0571
[no description available]		3.0910
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		01.9810
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		01.9810
Ear Infection
[description not available]		01.9910